CAPR

Capricor Therapeutics, Inc.

Price Chart

Latest Quote

$28.38

+0.43 (+1.54%)

Current Price

Previous Close	$27.95
Open	$28.28
Day High	$29.27
Day Low	$27.66
Volume	3,055,629

Fetched: 2026-06-19T07:56:57

Stock Information

Shares Outstanding	57.91M
Total Debt	$14.78M
Cash Equivalents	$278.61M
Net Income	$-114.59M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.64B
EPS (TTM)	$-2.32
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.24B
Income	$-114.59M
Book/sh	$4.83
Cash/sh	$4.81
Employees	231

Financial Ratios

Quick Ratio	8.28
Current Ratio	8.42
Debt/Eq	5.30

Returns & Margins

ROA	-31.23%
ROE	-56.40%

Ownership

Insider Ownership	9.47%
Institutional Ownership	59.72%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-37.16
PEG	0.38
P/B	5.87

Analyst Data

Recommendation	none
Target Price	$54.11

Technical Indicators

SMA20	$27.58
SMA50	$30.58
SMA200	$21.38
RSI	42.70
ATR	1.4607

Shares Float	48.55M
Short Float	21.11%
Short Ratio	10.34
Volatility	0.37
Rel Volume	3.31

Performance History

Week	+13.34%
Month	+5.42%
Quarter	-8.95%
6 Months	+9.07%
YTD	+0.25%
Year	+132.81%
3 Years	+494.97%
5 Years	+537.75%
10 Years	-35.94%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$28.38	3,095,000
2026-06-17	$27.95	1,460,400
2026-06-16	$26.05	654,900
2026-06-15	$26.72	985,700
2026-06-12	$25.80	773,500
2026-06-11	$25.04	1,220,500
2026-06-10	$25.33	1,484,400
2026-06-09	$26.01	976,400
2026-06-08	$26.16	640,700
2026-06-05	$26.71	578,200
2026-06-04	$27.95	584,200
2026-06-03	$27.64	664,900
2026-06-02	$27.34	895,800
2026-06-01	$28.53	726,400
2026-05-29	$29.96	841,100
2026-05-28	$29.11	417,300
2026-05-27	$29.14	553,600
2026-05-26	$29.36	674,600
2026-05-22	$28.87	569,700
2026-05-21	$29.58	893,300
2026-05-20	$29.01	1,123,700
2026-05-19	$26.92	1,103,300

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

📰 Latest News

All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%

Stocktwits • 2026-06-17T14:24:59Z

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

MarketBeat • 2026-06-11T13:04:01Z

Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy

Insider Monkey • 2026-06-06T00:12:28Z

Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus

Simply Wall St. • 2026-05-13T12:18:04Z

Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid ...

GuruFocus.com • 2026-05-13T05:02:11Z

Capricor Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-12T22:08:11Z

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

BioPharma Dive • 2026-05-11T10:00:00Z

Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story

Motley Fool • 2026-05-10T11:21:01Z

A Look At Capricor Therapeutics (CAPR) Valuation After Phase 3 HOPE-3 Duchenne Data And FDA Review Progress

Simply Wall St. • 2026-05-09T00:28:25Z

How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story

Simply Wall St. • 2026-04-24T10:06:16Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$22,270,465	$25,178,066	$2,551,469
Operating Revenue	$0	$22,270,465	$25,178,066	$2,551,469
Expenses
Interest Expense	$3,045,725	$0	-	-
Total Expenses	$108,142,130	$64,833,707	$49,255,925	$32,248,852
Other Income Expense	$6,145,509	$2,097,656	$1,790,317	$677,851
Other Non Operating Income Expenses	$45,421	$7,471	$67,657	$190,582
Net Non Operating Interest Income Expense	$-3,045,725	$0	-	-
Interest Expense Non Operating	$3,045,725	$0	-	-
Operating Expense	$108,142,130	$64,833,707	$49,255,925	$32,248,852
General And Administrative Expense	$22,748,646	$14,213,893	$12,365,518	$10,319,353
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Net Interest Income	$-3,045,725	$0	-	-
Normalized Income	$-111,144,034	$-42,557,371	$-24,010,202	$-29,506,801
Net Income From Continuing And Discontinued Operation	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Total Operating Income As Reported	$-108,142,130	$-42,563,242	$-24,077,859	$-29,697,383
Net Income Common Stockholders	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Net Income	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Net Income Including Noncontrolling Interests	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Net Income Continuous Operations	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Pretax Income	$-105,042,346	$-40,465,586	$-22,287,542	$-29,019,532
Special Income Charges	$-157,519	$-112,805	$-6,041	$-34,266
Operating Income	$-108,142,130	$-42,563,242	$-24,077,859	$-29,697,383
Depreciation Amortization Depletion Income Statement	$938,889	$651,229	$442,368	$112,550
Depreciation And Amortization In Income Statement	$938,889	$651,229	$442,368	$112,550
Depreciation Income Statement	-	$651,229	$442,368	$112,550
Per Share
Diluted EPS	$-2.26	$-1.15	$-0.83	$-1.18
Basic EPS	$-2.26	$-1.15	$-0.83	$-1.18
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-106,207,668	$-41,130,557	$-24,731,637	$-29,651,521
Total Unusual Items	$6,100,088	$2,090,185	$1,722,660	$487,269
Total Unusual Items Excluding Goodwill	$6,100,088	$2,090,185	$1,722,660	$487,269
Reconciled Depreciation	$1,889,041	$1,425,214	$1,068,882	$533,131
EBITDA (Bullshit earnings)	$-100,107,580	$-39,040,372	$-23,008,977	$-29,164,252
EBIT	$-101,996,621	$-40,465,586	$-24,077,859	$-29,697,383
Diluted Average Shares	$46,478,416	$35,218,628	$26,778,360	$24,552,688
Basic Average Shares	$46,478,416	$35,218,628	$26,778,360	$24,552,688
Diluted NI Availto Com Stockholders	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Tax Provision	$1,600	$1,600	-	-
Gain On Sale Of Ppe	$-157,519	$-112,805	$-6,041	$-34,266
Gain On Sale Of Security	$6,257,607	$2,202,990	$1,728,701	$521,535
Research And Development	$84,454,595	$49,968,585	$36,448,039	$21,816,949
Selling General And Administration	$22,748,646	$14,213,893	$12,365,518	$10,319,353
Other Gand A	$7,216,396	$3,607,499	$3,186,898	$3,381,900
Salaries And Wages	$15,532,250	$10,606,394	$9,178,620	$6,937,453
Other Special Charges	-	-	-	-

Fetched: 2026-06-14

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Total Assets	$355,949,294	$170,481,086	$58,734,327	$50,094,910
Total Non Current Assets	$33,009,538	$7,095,819	$7,878,855	$7,206,176
Other Non Current Assets	$1,159,480	$221,700	$268,172	$268,172
Current Assets	$322,939,756	$163,385,267	$50,855,472	$42,888,734
Other Current Assets	$4,751,674	$1,500,901	$995,776	$919,892
Receivables	$59,167	$10,368,489	$10,371,993	$547,580
Accounts Receivable	$59,167	$10,368,489	$10,371,993	$547,580
Cash Cash Equivalents And Short Term Investments	$318,128,915	$151,515,877	$39,487,703	$41,421,262
Cash And Cash Equivalents	$287,847,312	$11,286,996	$14,694,857	$9,603,242
Goodwill And Other Intangible Assets	-	-	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$14,522,765	$1,451,114	$2,235,895	$2,560,109
Long Term Debt And Capital Lease Obligation	$14,320,389	$616,315	$1,486,783	$1,878,070
Current Debt And Capital Lease Obligation	$202,376	$834,799	$749,112	$682,039
Liabilities
Total Liabilities Net Minority Interest	$50,157,149	$25,018,750	$36,132,860	$38,308,816
Total Non Current Liabilities Net Minority Interest	$14,320,389	$3,992,574	$4,863,042	$14,722,261
Current Liabilities	$35,836,760	$21,026,176	$31,269,818	$23,586,555
Other Current Liabilities	$6,421,984	-	-	-
Current Deferred Liabilities	$12,000,000	$12,000,000	$24,270,465	$17,980,599
Payables And Accrued Expenses	$17,212,400	$8,191,377	$6,250,241	$4,923,917
Payables	$1,654,754	$3,283,712	$6,250,241	$4,923,917
Accounts Payable	$1,654,754	$3,283,712	$6,222,762	$4,834,683
Other Non Current Liabilities	-	$3,376,259	$3,376,259	$3,376,259
Non Current Deferred Liabilities	-	-	$0	$9,467,932
Equity
Common Stock Equity	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Total Equity Gross Minority Interest	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Stockholders Equity	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Gains Losses Not Affecting Retained Earnings	$283,154	$1,026,955	$235,813	$105,244
Other Equity Adjustments	$283,154	$1,026,955	$235,813	$105,244
Retained Earnings	$-304,878,485	$-199,834,539	$-159,367,353	$-137,079,811
Other
Ordinary Shares Number	$57,370,909	$45,582,288	$31,148,320	$25,241,402
Share Issued	$57,370,909	$45,582,288	$31,148,320	$25,241,402
Tangible Book Value	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Invested Capital	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Working Capital	$287,102,996	$142,359,091	$19,585,654	$19,302,179
Capital Lease Obligations	$14,522,765	$1,451,114	$2,235,895	$2,560,109
Total Capitalization	$305,792,145	$145,462,336	$22,601,467	$11,786,094
Additional Paid In Capital	$610,330,105	$344,224,338	$181,701,859	$148,735,420
Capital Stock	$57,371	$45,582	$31,148	$25,241
Common Stock	$57,371	$45,582	$31,148	$25,241
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$14,320,389	$616,315	$1,486,783	$1,878,070
Current Deferred Revenue	$12,000,000	$12,000,000	$24,270,465	$17,980,599
Current Capital Lease Obligation	$202,376	$834,799	$749,112	$682,039
Current Accrued Expenses	$15,557,646	$4,907,665	-	-
Net PPE	$31,850,058	$6,874,119	$7,610,683	$6,938,004
Accumulated Depreciation	$-5,150,593	$-3,450,055	$-2,206,055	$-1,181,625
Gross PPE	$37,000,651	$10,324,174	$9,816,738	$8,119,629
Leases	$2,785,395	$2,501,207	$2,129,102	$1,393,230
Construction In Progress	$11,436,953	$0	-	-
Other Properties	$22,269,624	$7,630,884	$7,499,639	$6,587,063
Machinery Furniture Equipment	$508,679	$192,083	$187,997	$139,336
Properties	$0	$0	$0	$0
Other Short Term Investments	$30,281,603	$140,228,881	$24,792,846	$31,818,020
Non Current Deferred Revenue	-	-	$0	$9,467,932
Dueto Related Parties Current	-	-	$27,479	$89,234

Fetched: 2026-06-14

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-81,535,457	$-41,534,717	$-27,644,078	$1,556,906
Operating Activities
Operating Cash Flow	$-69,811,261	$-39,995,742	$-25,596,545	$4,916,637
Cash Flow From Continuing Operating Activities	$-69,811,261	$-39,995,742	$-25,596,545	$4,916,637
Operating Gains Losses	$157,519	$112,805	$6,041	$34,266
Investing Activities
Capital Expenditure	$-11,724,196	$-1,538,975	$-2,047,533	$-3,359,731
Investing Cash Flow	$97,479,281	$-116,183,868	$5,108,210	$-35,072,507
Cash Flow From Continuing Investing Activities	$97,479,281	$-116,183,868	$5,108,210	$-35,072,507
Financing Activities
Issuance Of Capital Stock	$237,033,938	$152,321,576	$25,515,349	$4,803,534
Financing Cash Flow	$248,892,296	$152,771,749	$25,579,950	$4,873,838
Cash Flow From Continuing Financing Activities	$248,892,296	$152,771,749	$25,579,950	$4,873,838
Net Common Stock Issuance	$237,033,938	$152,321,576	$25,515,349	$4,803,534
Common Stock Issuance	$237,033,938	$152,321,576	$25,515,349	$4,803,534
Other
Interest Paid Supplemental Data	$0	$0	$0	$0
Income Tax Paid Supplemental Data	$1,600	$1,600	$0	$0
End Cash Position	$287,847,312	$11,286,996	$14,694,857	$9,603,242
Beginning Cash Position	$11,286,996	$14,694,857	$9,603,242	$34,885,274
Changes In Cash	$276,560,316	$-3,407,861	$5,091,615	$-25,282,032
Proceeds From Stock Option Exercised	$11,858,358	$450,173	$64,601	$70,304
Net Investment Purchase And Sale	$109,203,477	$-114,644,893	$7,155,743	$-31,712,776
Sale Of Investment	$260,595,875	$93,796,269	$104,597,249	$82,505,961
Purchase Of Investment	$-151,392,398	$-208,441,162	$-97,441,506	$-114,218,737
Net PPE Purchase And Sale	$-11,724,196	$-1,538,975	$-2,047,533	$-3,359,731
Purchase Of PPE	$-11,724,196	$-1,538,975	$-2,047,533	$-3,359,731
Change In Working Capital	$12,199,681	$-10,784,478	$-11,752,040	$28,748,454
Change In Payables And Accrued Expense	$5,983,992	$1,941,136	$1,326,323	$1,208,158
Change In Prepaid Assets	$-4,093,633	$-458,653	$-75,884	$240,045
Change In Receivables	$10,309,322	$3,504	$-9,824,413	$-155,830
Other Non Cash Items	$3,761,184	$-47,261	$-24,282	$161,740
Stock Based Compensation	$17,225,260	$9,765,164	$7,392,396	$4,458,578
Depreciation Amortization Depletion	$1,889,041	$1,425,214	$1,068,882	$533,131
Depreciation And Amortization	$1,889,041	$1,425,214	$1,068,882	$533,131
Depreciation	$1,889,041	$1,425,214	$1,068,882	$533,131
Gain Loss On Sale Of PPE	$157,519	$112,805	$6,041	$34,266
Net Income From Continuing Operations	$-105,043,946	$-40,467,186	$-22,287,542	$-29,019,532
Change In Other Working Capital	-	$-12,270,465	$-3,178,066	$27,448,531
Change In Other Current Assets	-	-	$0	$7,550
Change In Payable	-	-	$1,326,323	$1,208,158
Change In Account Payable	-	-	$1,326,323	$1,208,158
Asset Impairment Charge	-	-	-	$0
Amortization Cash Flow	-	-	-	$0
Amortization Of Intangibles	-	-	-	$0
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Issuance	-	-	-	-
Change In Other Current Liabilities	-	-	-	-

Fetched: 2026-06-14